Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
| 5.49 Data as of Mar 06 |  -0.25 / -4.36%Today’s Change | 2.05 Today|||52-Week Range 7.09 | +2.98% Year-to-Date |
Latest MACK News | Press Releases
| Should You Worry About the Short Interest in Merrimack (MACK)? - Tale of the Tape Mar 05 / Zacks.com | MACK: Insiders Vs. Shorts Mar 03 / TheStreet.com |
| After-Hours Movers: BV, SWHC, AVAV, CTIC Moving Higher, HCI, BOBE, CHEF, THOR Lower Mar 04 / Benzinga | Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceutic... Feb 27 / MotleyFool.com |
Today’s Trading
| Previous close | 5.74 |
| Today’s open | 5.74 |
| Day’s range | -- - -- |
| Volume | 1,714,166 |
| Average volume (3 months) | 1,794,524 |
| Market cap | $565.7M |
| Dividend yield | -- |
Data as of 03/06/2014
Growth & Valuation
| Earnings growth (last year) | -5.32% |
| Earnings growth (this year) | +15.61% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -2.32% |
| P/E ratio | NM |
| Price/Sales | 11.04 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ACRXAcelRx Pharmaceutica... | -0.02 | -0.15% |
| RVNCRevance Therapeutics... | +1.11 | +3.51% |
| DRNADicerna Pharmaceutic... | -3.89 | -9.97% |
| ITCIITI Inc | +0.86 | +4.93% |
Data as of 03/06/2014
Financials
| Next reporting date | May 13, 2014 |
| EPS forecast (this quarter) | -$0.32 |
| Annual revenue (last year) | $47.8M |
| Annual profit (last year) | -$130.9M |
| Net profit margin | -273.98% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Robert J. Mulroy |
Senior Vice President- Operations William M. McClements |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
